Plasma lipid peroxidation and progression of disability in multiple sclerosis

Eur J Neurol. 2007 May;14(5):529-33. doi: 10.1111/j.1468-1331.2007.01739.x.

Abstract

Oxidative stress has been implicated in the pathophysiology of multiple sclerosis (MS), but its relation to disease progression is uncertain. To evaluate the relationship of plasma lipid peroxidation with progression of disability in MS, we measured blood plasma fluorescent lipid peroxidation products (PFLPP) levels in 23 patients with RRMS with a benign course, 32 with secondary progressive MS, 24 with primary progressive MS and 30 healthy controls. None of the patients had a relapse within the previous 3 months. Progression of disability was evaluated during a follow-up period of 5 years by the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Severity Score (MSSS). We found plasma PFLPP levels elevated in patients with MS compared with controls (P < 0.0001), but there was no difference between patients with a benign and progressive disease course. There was no correlation between PFLPP levels and worsening of disability on the EDSS and speed of progression on the MSSS. Our data suggest that there is no relation between the degree of oxidative stress in plasma and progression of disability in MS.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Biomarkers
  • Brain / metabolism
  • Brain / physiopathology
  • Disability Evaluation
  • Disease Progression
  • Female
  • Fluorescent Dyes
  • Follow-Up Studies
  • Humans
  • Lipid Peroxidation*
  • Lipids / blood*
  • Male
  • Middle Aged
  • Multiple Sclerosis / blood*
  • Multiple Sclerosis / physiopathology
  • Oxidative Stress*
  • Predictive Value of Tests
  • Up-Regulation

Substances

  • Biomarkers
  • Fluorescent Dyes
  • Lipids